These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29051077)

  • 1. Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.
    Ely S; Forsberg P; Ouansafi I; Rossi A; Modin A; Pearse R; Pekle K; Perry A; Coleman M; Jayabalan D; Di Liberto M; Chen-Kiang S; Niesvizky R; Mark TM
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):825-833. PubMed ID: 29051077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
    Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
    Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response.
    Sidiqi MH; Aljama MA; Jevremovic D; Morice WG; Timm M; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Leung N; Hogan WJ; Muchtar E; Lust JA; Rajkumar VS; Gertz MA
    Bone Marrow Transplant; 2019 Mar; 54(3):442-447. PubMed ID: 30087461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
    Al-Quran SZ; Yang L; Magill JM; Braylan RC; Douglas-Nikitin VK
    Hum Pathol; 2007 Dec; 38(12):1779-87. PubMed ID: 17714757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort.
    Møller HE; Preiss BS; Pedersen P; Kristensen IB; Hansen CT; Frederiksen M; Abildgaard N; Møller MB
    APMIS; 2015 Aug; 123(8):652-8. PubMed ID: 26152595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients.
    Ninkovic S; Purton LE; Harrison SJ; Quach H
    Haematologica; 2024 May; 109(5):1487-1500. PubMed ID: 37855027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Determination proliferative activity of myeloma cells in histologic material].
    Fabian P; Kren L; Nenutil R
    Cesk Patol; 2004 Apr; 40(2):46-9. PubMed ID: 15233016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.
    Aljama MA; Sidiqi MH; Lakshman A; Dispenzieri A; Jevremovic D; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame R; Kourelis TV; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
    Blood Adv; 2018 Nov; 2(22):3149-3154. PubMed ID: 30463914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
    Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
    Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haematologists usually over-estimate the percentage of CD138+ plasma cells in marrow biopsies.
    Chai KY; Boyke Berahmana AA; Morison IM
    Pathology; 2019 Oct; 51(6):647-648. PubMed ID: 31470997
    [No Abstract]   [Full Text] [Related]  

  • 12. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
    Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
    Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma cell maturity as a predictor of prognosis in multiple myeloma.
    Iriyama N; Miura K; Hatta Y; Uchino Y; Kurita D; Takahashi H; Sakagami H; Sakagami M; Kobayashi Y; Nakagawa M; Ohtake S; Iizuka Y; Takei M
    Med Oncol; 2016 Aug; 33(8):87. PubMed ID: 27383407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma.
    Han W; Jin Y; Xu M; Zhao SS; Shi Q; Qu X; Zhang R; Li J; Wu Y; Chen L
    Hematology; 2021 Dec; 26(1):510-517. PubMed ID: 34314294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.
    Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY
    Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.
    Vagnoni D; Travaglini F; Pezzoni V; Ruggieri M; Bigazzi C; Dalsass A; Mestichelli F; Troiani E; Falcioni S; Mazzotta S; Natale A; Angelini M; Ferretti S; Angelini S; Galieni P
    Br J Haematol; 2015 Aug; 170(4):523-31. PubMed ID: 26010293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
    Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
    Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
    Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients.
    Al Saleh AS; Parmar HV; Visram A; Muchtar E; Buadi FK; Go RS; Dispenzieri A; Kapoor P; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kourelis TV; Gertz MA; Kyle RA; Rajkumar SV; Kumar SK
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):596-601. PubMed ID: 32360276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma.
    Dunphy CH; Nies MK; Gabriel DA
    Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):248-54. PubMed ID: 17721267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.